The latest report by IMARC Group, titled “Emergency Contraceptive Pills Market by Type (Combination Pills, Progesterone Pills, and Others), Distribution Channel (Retail Stores, Online Stores, and Others), and Region 2023-2028,” finds that the global emergency contraceptive pills market size reached US$ 561.2 Million in 2022. Emergency contraceptive pills, or morning-after pills, are a form of birth control used to prevent pregnancy after unprotected sexual intercourse or contraceptive failure. These pills contain hormones, typically levonorgestrel or ulipristal acetate, that work by inhibiting or delaying ovulation, fertilization, or implantation of the fertilized egg into the uterus lining. For instance, one common type of emergency contraceptive pill is the levonorgestrel-based pill, available over-the-counter in many countries. It should be taken after unprotected intercourse, ideally within 72 hours, although its effectiveness decreases with time. Another option is ulipristal acetate, available with a prescription and effective up to 120 hours after unprotected sex. They are meant for occasional use when other forms of contraception fail or are not used. Additionally, emergency contraceptive pills are generally safe and have side effects such as nausea, fatigue, or changes in menstrual cycles.
Global Emergency Contraceptive Pills Market Trends:
The market is primarily driven by the significant increase in awareness and education regarding emergency contraception. In addition, public health campaigns, educational programs, and easy access to information are essential in informing individuals about the availability and proper usage of emergency contraceptive pills, thus influencing market growth. Moreover, several advances in pharmaceutical research led to the development of more effective and convenient emergency contraceptive pills, which increased consumer confidence in the products and their reliability, representing another major growth-inducing factor. Besides this, the easy availability of emergency contraceptive pills over the counter and through healthcare providers removed many barriers that previously hindered individuals from obtaining timely emergency contraception, which is accelerating the market growth. Along with this, the changing societal attitudes toward emergency contraception reduced the stigma associated with its use, allowing more individuals to discuss and seek these products, propelling the market growth. Apart from this, the implementation of several regulatory changes in some countries made it easier to access emergency contraception without a prescription, thus augmenting the market growth. Furthermore, the changing demographics, such as delayed family planning and a focus on career development, are escalating the demand for emergency contraception among women of reproductive age, thus creating a positive market outlook. Looking forward, IMARC Group expects the market value to reach US$ 736.7 Million by 2028, exhibiting a CAGR of 4.74% during the forecast period (2023-2028).
- Based on the type, the market has been categorized into combination pills, progesterone pills, and others. Presently, combination pills represent the leading segment.
- On the basis of the distribution channel, the market has been divided into retail stores, online stores, and others. Currently, retail stores hold the leading position in the market.
- Region-wise, the market has been divided into North America (the United States and Canada), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others), Latin America (Brazil, Mexico, and others), and Middle East and Africa. Among these, North America exhibits a clear dominance in the market.
- The competitive landscape of the industry has also been examined in the report, with some of the key players being Afaxys Pharma LLC, Foundation Consumer Healthcare LLC, Gedeon Richter Plc, HLL Lifecare Limited, Perrigo Company plc, Piramal Enterprises Ltd., and Syzygy Healthcare Solutions LLC.
|Base Year of the Analysis
||Combination Pills, Progesterone Pills, Others
|Distribution Channels Covered
||Retail Stores, Online Stores, Others
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Afaxys Pharma LLC, Foundation Consumer Healthcare LLC, Gedeon Richter Plc, HLL Lifecare Limited, Perrigo Company plc, Piramal Enterprises Ltd., Syzygy Healthcare Solutions LLC, etc.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
134 N 4th St.
Brooklyn, NY 11249, USA
Americas:- +1 631 791 1145 | Africa and Europe :- +44-702-409-7331 | Asia: +91-120-433-0800, +91-120-433-0800